Seroprevalence of protecting antibodies against mumps, measles and rubella in adults with HIV infection
E. Bissio, C. Biscayart, A. Botas, P. Ríos, P. Titanti, I. Cassetti
FUNCEI, Buenos Aires, Argentina
our knowledge, very little has been published about seroprevalence of
antibodies to mumps, measles and rubella in adults with HIV infection. We
hypothesized that impairment of immunity in these patients, even at high CD4
counts, might result in lower antibody prevalence and therefore result in susceptibility for infection and
subsequent risk of spreading these viruses.
The aim of this study was to determine seroprevalence of antibodies to measles,
mumps and rubella in HIV(+) patients between 18 and 45 years, and compare them
to prevalences in the general population.
descriptive study. All serologies for measles, mumps and rubella requested to
HIV(+) patients aged 18-45 years as screening in the last 2 years in an
infectious diseases center in Buenos Aires, Argentina were retrieved. We also
retrieved the serologies against the same viruses from HIV- patients (18-45
years) requested in the same period.
Results: We included 326
HIV+ patients with 819 serologies for mumps, rubella and/or measles. Mean (±SD)
age was 34.2 (±6.1) years, 88% were male. Mean nadir CD4 was 369.6 (±219.5)
cells/mm3. The other group consisted of 5458 HIV- patients; mean age was 31
(±5.9) years, 68% female.
The percentage of patients with negative antibodies for measles was 19.9% in
the HIV+ group and 17.2% in the other group (p=0.29). The percentage of
patients with negative antibodies for mumps was 14.2% in the HIV+ group and 11.8%
in the other group (p=0.3). For rubella, the percentages were 11.4% and 5.6%
respectively (p=0.0021). In the HIV+ group, the absence of antibodies to
measles, mumps and rubella was not associated with a nadir of CD4 < 200
(p=NS for the 3 comparisons).
seroprevalence of rubella antibodies differs between HIV+ and HIV- patients, this might be due to a recent rubella vaccination campaign for women in Argentina.
Granted by Fogarty-AITRP Grant#5D43TW001037.
Back to the Programme-at-a-Glance